Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04567303 · ClinicalTrials.gov registry record · Phase 1
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
A Phase 1 study of Macular Degeneration, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 1
- Development phase
- 177
- Enrollment target
- 20
- Study locations
NCT04567303: Active Phase 1 study of Macular Degeneration, sponsored by Hoffmann-La Roche.
NCT04567303 is a Phase 1 study of Macular Degeneration that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 177 participants, roughly in line with the 172-participant average among 26 other Macular Degeneration trials with a reported enrollment target. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04567303, a Phase 1 study of Macular Degeneration, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 177 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).
Conditions Studied
Interventions
- DRUG Zifibancimig
- DRUG Ranibizumab
- DEVICE Port Delivery Platform
Study Locations (20)
California
- The Retina Partners - Encino
- Retinal Consultants Med Group - Sacramento
- Orange County Retina Med Group - Santa Ana
- Macula Retina Vitreous Research Institute - Torrance
Florida
- Retina Specialty Institute - Pensacola
- Retina Vitreous Assoc of FL - St. Petersburg
- Southern Vitreoretinal Assoc - Tallahassee
- Retina Associates of Florida, LLC - Tampa
Maryland
- The Retina Care Center - Baltimore
- Johns Hopkins Med - Baltimore
- Retina Group of Washington - Chevy Chase
- Cumberland Valley Retina Consultants - Hagerstown
Arizona
- Barnet Dulaney Perkins Eye Center - Mesa
- Associated Retina Consultants - Phoenix
Michigan
- Foundation for Vision Research - Grand Rapids
- Associated Retinal Consultants - Royal Oak
Colorado
- Southwest Retina Consultants - Durango
Georgia
- Southeast Retina Center - Augusta
Illinois
- University Retina and Macula Associates, PC - Oak Forest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 1 |
What the registry record for NCT04567303 still lists
NCT04567303 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 172-participant average among 26 other Macular Degeneration trials with a reported enrollment target.
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Zifibancimig is the first listed.
NCT04567303 names 20 study sites across 9 states, led by California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT04567303 about?
NCT04567303 is a clinical study titled "Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration". This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).
What is the current status of trial NCT04567303?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2020-10-28. Estimated completion is 2026-08-01.
What conditions does trial NCT04567303 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT04567303?
The interventions under investigation include: Zifibancimig (DRUG), Ranibizumab (DRUG), Port Delivery Platform (DEVICE).
Who is sponsoring clinical trial NCT04567303?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04567303 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04567303's enrollment target sits among peer trials
177 8th of 26 higher than 19 of 26 other Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
COMPLETED · Phase 1
-
A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers
COMPLETED · Phase 1
-
Identification and Treatment of Feeder Vessels in Macular Degeneration
COMPLETED · Phase 1
-
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
COMPLETED · Phase 1
-
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
COMPLETED · Phase 1
-
Cooling Anesthesia for Intravitreal Injection
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI